Fig. 6: Treatment with IKK-16 overcomes resistance to sunitinib in a xenograft animal model of human ccRCC. | Cell Death & Disease

Fig. 6: Treatment with IKK-16 overcomes resistance to sunitinib in a xenograft animal model of human ccRCC.

From: The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma

Fig. 6

Subcutaneous PNX0010 tumors were established in 6-week-old male C.B17icr-scid mice. Treatment with sunitinib (Sun), IKK-16 or combination was carried out as described in Materials and methods section. Values are means (n = 5) ±SEM. *P = 0.0069 when compared vehicle with sunitinib treatment; **P < 0.0001 when compared sunitinib with sunitinib + IKK-16 treatment; ***P < 0.0001 when compared vehicle with sunitinib + IKK-16 treatment; ****P < 0.0001 when compared sunitinib with sunitinib + IKK-16 treatment at the end of the experiment.

Back to article page